Adolor Corp. and GlaxoSmithKline achieved initial top-line results of the Phase III Study 14CL314 of Entereg for the management of postoperative ileus (POI), by acceleration of the time to recovery of gastrointestinal (GI) function following bowel resection surgery. The study enrolled 654 patients scheduled to undergo bowel resection surgery. The results showed that a 12 mg dose of Entereg achieved a statistically significant difference compared to placebo for the primary endpoint, and for each ...